Company profile AFMD

Affimed N.V.
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to t...he most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli Show More
Quarter analysis & expected interest

There is not enough data for Affimed N.V. to provide analysis

Correlation between past revenue and Affimed N.V. search interest

There is not enough data for Affimed N.V. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Affimed N.V. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 13:24:08.

After 39 days of this quarter the interest is at 79.0. Based on that we can calculate that during remaining 52 days it will total up to 184.0.
AFMD stock expected interest is significantly higher compared to previous quarter (+47.2%) and same quarter last year (+49.6%).

YearQ1Q2Q3Q4
2019206
225
9.2% QoQ
132
-41.3% QoQ
110
-16.7% QoQ
2020 162
-21.4% YoY 47.3% QoQ
192
-14.7% YoY 18.5% QoQ
155
17.4% YoY -19.3% QoQ
284
158.2% YoY 83.2% QoQ
2021 248
53.1% YoY -12.7% QoQ
508
164.6% YoY 104.8% QoQ
174
12.3% YoY -65.7% QoQ
184
-35.2% YoY 5.7% QoQ
2022 137
-44.8% YoY -25.5% QoQ
158
-68.9% YoY 15.3% QoQ
60
-65.5% YoY -62.0% QoQ
94
-48.9% YoY 56.7% QoQ
2023 123
-10.2% YoY 30.9% QoQ
107
-32.3% YoY -13.0% QoQ
83
38.3% YoY -22.4% QoQ
125
33.0% YoY 50.6% QoQ
2024 79
-35.8% YoY -36.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and AFMD stock search interestLast update: February 08 2024 13:24:08.
Correlation coefficient between keyword and revenue is -0.59
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 13:24:12.

The average 5 years interest of AFMD stock was 13.59 per week.
The last year interest of AFMD stock compared to the last 5 years has changed by -32.08%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -36.17%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AFM13 clinical trial to provide analysis

Correlation between past revenue and AFM13 clinical trial search interest

There is not enough data for AFM13 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AFM13 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AFM24 clinical trial to provide analysis

Correlation between past revenue and AFM24 clinical trial search interest

There is not enough data for AFM24 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AFM24 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 04 2023 01:26:46.

After 34 days of this quarter the interest is at 310.0. Based on that we can calculate that during remaining 58 days it will total up to 839.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 493
2019 730
48.1% QoQ
709
-2.9% QoQ
661
-6.8% QoQ
658
33.5% YoY -0.5% QoQ
2020 690
-5.5% YoY 4.9% QoQ
578
-18.5% YoY -16.2% QoQ
604
-8.6% YoY 4.5% QoQ
559
-15.0% YoY -7.5% QoQ
2021 610
-11.6% YoY 9.1% QoQ
635
9.9% YoY 4.1% QoQ
626
3.6% YoY -1.4% QoQ
670
19.9% YoY 7.0% QoQ
2022 764
25.2% YoY 14.0% QoQ
843
32.8% YoY 10.3% QoQ
769
22.8% YoY -8.8% QoQ
735
9.7% YoY -4.4% QoQ
2023 827
8.2% YoY 12.5% QoQ
806
-4.4% YoY -2.5% QoQ
785
2.1% YoY -2.6% QoQ
310
-57.8% YoY -60.5% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cancer immunotherapy search interestLast update: November 04 2023 01:26:45.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 04 2023 01:26:46.

The average 5 years interest of Cancer immunotherapy was 53.88 per week.
The last year interest of Cancer immunotherapy compared to the last 5 years has changed by 12.75%.
The interest for Cancer immunotherapy is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 12.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 00:06:45.

After 39 days of this quarter the interest is at 273.0. Based on that we can calculate that during remaining 52 days it will total up to 637.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019419
598
42.7% QoQ
538
-10.0% QoQ
603
12.1% QoQ
2020 688
64.2% YoY 14.1% QoQ
633
5.9% YoY -8.0% QoQ
510
-5.2% YoY -19.4% QoQ
475
-21.2% YoY -6.9% QoQ
2021 665
-3.3% YoY 40.0% QoQ
494
-22.0% YoY -25.7% QoQ
418
-18.0% YoY -15.4% QoQ
532
12.0% YoY 27.3% QoQ
2022 521
-21.7% YoY -2.1% QoQ
546
10.5% YoY 4.8% QoQ
685
63.9% YoY 25.5% QoQ
565
6.2% YoY -17.5% QoQ
2023 676
29.8% YoY 19.6% QoQ
486
-11.0% YoY -28.1% QoQ
586
-14.5% YoY 20.6% QoQ
532
-5.8% YoY -9.2% QoQ
2024 273
-59.6% YoY -48.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Biotechnology companies search interestLast update: February 09 2024 00:06:44.
Correlation coefficient between keyword and revenue is -0.25
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 00:06:47.

The average 5 years interest of Biotechnology companies was 43.84 per week.
The last year interest of Biotechnology companies compared to the last 5 years has changed by -0.55%.
The interest for Biotechnology companies is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by -5.65%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Affimed N.V. investors to provide analysis

Correlation between past revenue and Affimed N.V. investors search interest

There is not enough data for Affimed N.V. investors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Affimed N.V. investors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Affimed N.V. Germany to provide analysis

Correlation between past revenue and Affimed N.V. Germany search interest

There is not enough data for Affimed N.V. Germany to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Affimed N.V. Germany to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Affimed N.V. news to provide analysis

Correlation between past revenue and Affimed N.V. news search interest

There is not enough data for Affimed N.V. news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Affimed N.V. news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Affimed N.V. career to provide analysis

Correlation between past revenue and Affimed N.V. career search interest

There is not enough data for Affimed N.V. career to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Affimed N.V. career to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for AFMD
Earnings date: 2024-03-21 After close
Company name: Affimed N.V.
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-07-21T12:18:32-04:00

SEC
25-NSE Form - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities - Affimed N.V. (0001608390) (Subject)

2025-05-20T16:01:22-04:00

SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - Affimed N.V. (0001608390) (Subject)

2025-05-14T17:03:51Z

Analyst Upgrades
HC Wainwright & Co. Downgrades Affimed to Neutral

2025-05-14T07:16:40-04:00

SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Affimed N.V. (0001608390) (Filer)

2025-05-14T10:45:00Z

GlobeNewswire
Affimed Announces Receipt of Nasdaq Delisting Notice

2025-05-13T22:05:24Z

Analyst Upgrades
Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

2025-05-13T08:22:43-04:00

SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Affimed N.V. (0001608390) (Filer)

2025-05-13T12:15:00Z

GlobeNewswire
Affimed Announces Filing for the Opening of Insolvency Proceedings

2025-05-13T10:54:23Z

Analyst Upgrades
Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

2025-05-01T16:05:20-04:00

SEC
NT 20-F Form - Notification of inability to timely file Form 20-F - Affimed N.V. (0001608390) (Filer)

2025-04-29T14:00:00Z

GlobeNewswire
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

2025-04-23T14:05:00Z

GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

2025-04-21T08:32:58-04:00

SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Affimed N.V. (0001608390) (Filer)

2025-04-21T10:30:00Z

GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

2025-03-25T20:30:00Z

GlobeNewswire
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting